Forte Biosciences Inc (FBRX)
0.6962
0.00 (0.00%)
USD |
NASDAQ |
Mar 28, 16:00
0.6962
0.00 (0.00%)
After-Hours: 20:00
Forte Biosciences Cash from Financing (TTM): 24.68M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 24.68M |
September 30, 2023 | 24.70M |
June 30, 2023 | 7.367M |
March 31, 2023 | 7.281M |
December 31, 2022 | 7.241M |
September 30, 2022 | 7.257M |
June 30, 2022 | -0.186M |
Date | Value |
---|---|
March 31, 2022 | -0.105M |
December 31, 2021 | -0.044M |
September 30, 2021 | 42.39M |
June 30, 2021 | 42.56M |
March 31, 2021 | 66.65M |
December 31, 2020 | 66.67M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.186M
Minimum
Jun 2022
66.67M
Maximum
Dec 2020
22.80M
Average
7.367M
Median
Jun 2023
Cash from Financing (TTM) Benchmarks
CEL-SCI Corp | 8.678M |
AIM ImmunoTech Inc | 0.338M |
IGC Pharma Inc | 2.856M |
NovaBay Pharmaceuticals Inc | 4.971M |
Protalix BioTherapeutics Inc | 24.67M |